High expression of the yeast syntaxin-related Vam3 protein suppresses the protein transport defects of a pep12 null mutant  by Götte, M. & Gallwitz, D.
FEBS Letters 411 (1997) 48-52 FEBS 18723 
High expression of the yeast syntaxin-related Vam3 protein suppresses 
the protein transport defects of a pepl2 null mutant 
M. Gotte, D. Gallwitz* 
Max-Planck-Institute for Biophysical Chemistry, Department of Molecular Genetics, P.O. Box 2841, D-37018 Gottingen, Germany 
Received 16 April 1997 
Abstract The Pepl2 protein of Saccharomyces cevevisiae is a 
member of the syntaxin family thought to function as target 
membrane receptor (t-SNARE) for vesicular intermediates 
travelling between the Golgi apparatus and the vacuole. 
Exploiting the temperature-sensitive growth phenotype of 
pepl2 deletion strains, we identified VAM3 as a multicopy 
suppressor. Vam3p is another syntaxin-related protein which on 
high expression restored vacuole acidification of pepl2 null 
mutants and effectively suppressed their sorting and maturation 
defects of vacuolar hydrolases. We conclude that Vam3p acts 
either as a bypass suppressor or by functionally replacing Pepl2p 
at an endosomal, prevacuolar compartment. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The vacuole of the yeast Saccharomyces cerevisiae is the 
functional equivalent of the mammalian lysosome. Apar t 
from functions in the storage of metabolites and the regula-
tion of ion homeostasis in the cytosol, its most prominent role 
is the degradation of macromolecules [[1], for review]. A vari-
ety of hydrolases reside in the acidic lumen, most of them 
being synthesized as inactive precursors in the ER. After pass-
ing the early stages of the secretory pathway, soluble vacuolar 
hydrolases are actively sorted away from secretory proteins in 
a late Golgi compartment and delivered to the vacuole via 
intermediate endosome-like compartments [[2], for review]. 
U p o n arrival in the vacuole, the precursor forms are typically 
activated by proteolytic processing [[3,4] for review]. 
Mutants defective in vacuole function have been isolated 
through screening for both biochemical and morphological 
phenotypes: pep mutants [5] were isolated due to their prop-
erty of missorting the vacuolar hydrolase proteinase A (PrA) 
which is also required for activation of the proteinases B 
(PrB) and C (PrC = carboxypeptidase Y, CPY); vps mutants 
[6,7] are characterized by the secretion of the Golgi-modified 
precursor form of CPY, and vam mutants [8] exhibit an al-
tered vacuolar morphology, such as fragmentation. 
Interestingly, in some of these mutants members of gene 
families are affected which have been identified as general 
components of vesicular t ransport [9,10]. For example, the 
small GTPases Ypt51p and Ypt7p have also been isolated 
as Vps21p and Vam4p, respectively [11-14]. Recently, the 
yeast Pep 12 protein has been shown to act in a vesicular 
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transport step between the Golgi apparatus and the vacuole 
[15]. Pep l2p is a t ransmembrane protein of 288 amino acids 
which exhibits 25% identity and 56% similarity to rat syntaxin 
6 [16]. It is thought to act as a so-called t -SNARE (target 
membrane soluble N S F attachment protein receptor; 
N S F = A^-ethyl-maleimide-sensitive fusion protein) in the 
docking of t ransport vesicles at a still ill-defined, prevacuolar 
(endosomal) compartment [15,17]. Cells carrying a disruption 
of the PEP12 gene are characterized by a single enlarged, 
acidification-defective vacuole, the accumulation of 50 nm 
vesicles and maturat ion and sorting defects of several vacuo-
lar hydrolases [15]. Fur thermore, pep 12 deletion strains exhib-
it a growth defect at 38°C. We exploited this phenotype to 
screen for multicopy suppressors of the deletion of PEP 12. 
Multicopy suppressor screening previously led to the identifi-
cation of many components of the vesicular t ransport machi-
neries, such as t -SNAREs, v-SNAREs (vesicle membrane 
SNARE) and S£C7-homologues [18-21]. 
We identified the VAM3 gene as a potent multicopy sup-
pressor of the deletion of PEP12. According to its primary 
sequence, the Vam3 protein is a member of the syntaxin fam-
ily [22]. Our results suggest that Vam3p acts as a t -SNARE 
either replacing Pep l2p or activating an alternative, Pep l2p-
independent pathway. 
2. Materials and methods 
2.1. Strains, growth conditions and genetic methods 
The following yeast strains were used in this study: MSUC-3D: 
Mata ura3 leu2 his3 trpl lys2 (this laboratory); YMG7: MSUC-3D 
pepl2::kanMX4 (this study); SEY6210: Mata suc2-D9 ura3-52 leu2-
3,113 his3-D200 trpl-D901 lys2-801 [6]; YMG5: SEY6210 pepl2:: 
kanMX4 (this study); YMG8: SEY6210 vam3::LEU2 (this study). 
Manipulations of E. coli and DNA were performed according to 
standard procedures [23], Yeast strains were grown in 1% yeast ex-
tract (Gibco, Eggenstein), 2% peptone 140 (Gibco, Eggenstein), 2% 
glucose (YEPD), or in synthetic glucose medium (SD) supplemented 
as necessary [24]. Solid media were prepared by adding 2% agar 
(Gibco, Eggenstein). Lithium acetate transformation of yeast cells 
was performed as previously described [25]. 
2.2. Construction of recombinant plasmids 
To clone the PEP 12 gene, a fragment encompassing codons 14 to 
189 was amplified using standard PCR techniques. The PCR fragment 
was digoxygenin-labelled using the DIG-labelling kit (Boehringer 
Mannheim) and used to screen approximately 19000 E. coli clones 
of a YEpl3-based genomic yeast library as described previously [18]. 
Plasmids were isolated from two candidate colonies and the presence 
of PEP12 was verified by Southern blotting and DNA-sequencing 
using the Sequenase 2.0 kit (USB, Braunschweig). A 1245 bp Clall 
Nsi\-PEP12 fragment was subcloned into Clall Pstl-cut pBluescript II 
KS+ (Stratagene, Heidelberg) to create pMGl. A 1290 bp XhoVEagl 
fragment of pMGl was subcloned into the respective polylinker sites 
of the shuttle vectors pRS316 [26] and pRS326 [27] to create pMG13 
and pMG6, respectively. The VAM3 gene was cloned as follows. 
Utilizing the X/foI-polylinker site of the library vector pTSS25, a 
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1462 bp Xho\(TaqT)l'EagI fragment of VAM3 representing base pairs 
518930 to 520392 of chromosome XV was cloned into XhoIIEagl-cut 
pRS326 and pRS316 to create pMG49 and pMG56, respectively. The 
plasmid pMG48 (pBS-VAM3) was constructed by subcloning the 
1768 bp Avrll/Nsil VAM3 fragment of the original suppressor plas-
mid pTSSl into PstVXbal-cat pBluescript II KS+. The SED5 gene, 
cloned from a genomic library, was inserted into pRS326 as a 4.2 kb 
Xbal fragment. All plasmid constructions were controlled by sequenc-
ing. 
2.3. Gene disruptions 
The PEP12 gene was deleted using the LFH-PCR disruption tech-
nique as described by Wach [28]. The oligonucleotides MG56 5'-
AATTAACCCTCACTAAGGG-3' and MG57 5'-CCCTTTAGT-
GAGGGTTAATTCATCTCAACACAATTATTG-3' were used to 
amplify the 5'-megaprimer, whereas MG58 5'-GCCCTATAGT-
GAGTCGTATTACGGCTTCAGACGAGCTAAGG-3' and MG59 
5'-GTAATACGACTCACTATAGGGC-3' were used to amplify the 
3'-megaprimer under standard PCR conditions. Single-step gene dis-
ruption of the chromosomal VAM3 gene was done with a linear DNA 
fragment. Part of the protein-coding region of the gene was removed 
and replaced by the yeast marker gene LEU2 as follows. From 
pMG48, a blunt-ended 928 bp StuAlBsiEW fragment containing 
more than 90% of the protein-coding region of VAM3 (—166 to 
+792) was removed and replaced by LEU2 on a 2.2 kb Hpal frag-
ment. The vam3 deletion strain YMG8 was constructed by transform-
ing the haploid strain SEY6210 with a 2.7 kb NotI(AwII)IDraI 
vam3::LEU2 fragment which contained 140 bp and 280 bp of se-
quence extending 5' and 3' from the deletion end points. In all cases, 
correct integration was verified by Southern blot analysis using the 
ECL system (Amersham Buchler, Braunschweig). 
2.4. Radiolabelling and immunoprecipitation 
Pulse-chase experiments were performed exactly as described previ-
ously by Tsukada and Gallwitz [29] using the anti-CPY- and anti-
alkaline phosphatase (ALP) antisera described by Benli et al. [30]. 
2.5. Vital staining 
Quinacrine staining of yeast vacuoles was essentially performed as 
described in Weisman et al. [31]. Staining with CDCFDA was done 
exactly as described by Roberts et al. [32], 
2.6. SDS-PAGE and Western blotting 
SDS-PAGE [33] and Western blotting [34] were performed as de-
scribed previously. For steady-state Western blotting, yeast extracts 
were prepared by alkaline lysis followed by TCA precipitation as 
described [30]. The monoclonal antibody specific for proteinase A 
was a kind gift from Akihiko Nakano (Tokyo). Polyclonal antisera 
specific for CPY and ALP have been described previously [30], Sec-
ondary horseradish-peroxidase labelled anti-mouse or anti-rabbit IgG 
antibodies were from Amersham Buchler, Braunschweig. The ECL-
system (Amersham Buchler, Braunschweig) was used for signal detec-
tion after Western blotting. 
2.7. Reagents 
Except stated otherwise, all reagents were from Sigma (Deisenho-
fen, Germany). 
3. Results 
In the course of our investigations on interacting partners 
for the small GTPases Ypt51p [12] and Ypt7p [13], we ob-
served a weak genetic interaction of YPT51 and PEP 12 (M. 
Gotte, J.-S. Yoo, D. Gallwitz, unpublished). To identify addi-
tional components of the vesicular transport pathway from 
the Golgi apparatus to the vacuole, we searched for multicopy 
suppressors utilizing the temperature-sensitive phenotype of 
pepl2 null mutants. The pepl2 deletion strain YMG7 was 
transformed with a pRS326-based yeast genomic library 
[27]. Transformants on selective plates (-Ura) were incubated 
for 1 day at 30°C and thereafter at 38°C for 2 days. Of 
approximately 50000 transformants, 58 were able to grow 
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Fig. 1. Suppression of the temperature-sensitive growth defect of a 
pepl2 null mutant. 5 ul of logarithmic growing YMG5 (pep!2~) 
cells transformed with the plasmids indicated were spotted onto SD-
Ura agar plates at concentrations of 1000, 100, and 10 cells/ul and 
incubated at 30°C (upper panel) or 38°C (lower panel) for 3 days, 
respectively, vector = pRS326; 2a = multicopy plasmid. 
at 38°C. Plasmids were isolated and amplified in E. coli. Plas-
mids exhibiting different restriction patterns were retrans-
formed into YMG7 and retested for suppressor activity. 
Among these plasmids, 14 inserts contained the authentic 
PEP12 gene. Two plasmids (pTSSl/pTSS25) contained over-
lapping DNA fragments of 6.6 kb and 8.0 kb with only one of 
the several open reading frames (ORF) (YOR106w) being 
present in both. This ORF is identical with VAM3 (GenBank 
accession #U57827), which encodes a syntaxin-related protein 
of 283 amino acids. To confirm that the suppressing activity 
could be ascribed to the VAM3 gene, the gene was subcloned 
into pRS326 and retested for suppression of the growth defect 
of the pepl2 null mutants YMG5 and YMG7 at 38°C. As can 
be seen in Fig. 1, high expression of VAM3 conferred resist-
ance to elevated temperatures in YMG5. Even expression 
from a centromeric plasmid relieved the temperature sensitiv-
ity as compared to cells transformed with the empty vector 
(data not shown). In contrast, high expression of SED5, 
which encodes a structurally related t-SNARE acting in ER-
to-Golgi transport [35] did not restore growth of YMG5 cells 
at the non-permissive temperature. The same effects were ob-
served in YMG7 (results not shown). As many studies on vps 
mutants have been carried out in the genetic background of 
YMG5, this strain was chosen for further analyses. 
Due to a malfunction in the assembly of two subunits of the 
vacuolar ATPase [36], pepl2 mutants exhibit a defect in va-
cuole acidification [37] which can be monitored using the basic 
fluorescent dye quinacrine [31]. As can be seen in Fig. 2b, 
quinacrine did not stain the vacuole of pepl2 mutant cells 
transformed with the empty vector. In contrast, expression 
from the multicopy plasmid of both the PEP12 and the 
VAM3 gene led to stained vacuoles indicating restoration of 
vacuole acidification (Fig. 2d,f). While expression of PEP12 
from a centromeric plasmid allowed vacuole staining, low ex-
pression of VAM3 from a single copy plasmid was not suffi-
cient to restore vacuole acidification (results not shown). Oc-
casionally, a few weakly stained cells could be observed. 
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Fig. 2. Suppression of the vacuolar acidification defect of a pepl2 
null mutant. The vacuoles of YMG5 (pepl2~) cells transformed 
with pRS326 (a,b), pRS326-PEP12 (c,d), pRS326-VAM3 (e,f) or 
pRS326-SED5 (g,h) were stained with quinacrine as described in 
Section 2 and viewed by Nomarski (a,c,e) or fluorescence (b,d,f) mi-
croscopy, respectively. 
Importantly, high expression of SED5 could not suppress the 
vacuole acidification defect of YMG5 (Fig. 2h). 
All vps and pep mutants are defective in vacuolar protein 
maturation and they missort the soluble vacuolar hydrolases 
proteinase A (PrA) and CPY [5-7]. As shown in steady-state 
Western blots (Fig. 3), the mature forms of PrA (42 kDa) and 
CPY (61 kDa) appeared to be absent from pep12 null mutant 
cells but they were readily detectable in the pepl2~ strains 
transformed with either pRS326-PEP12 or pRS326-VAM3. 
In the case of PrA, the immature ER- and Golgi-modified 
forms (48 and 44 kDa species) could be seen in pepl2~ cells. 
They disappeared completely in P£'P72-expressing cells and, 
to a large extent, on high expression of VAM3. In contrast, 
high expression of SED5 had no effect on the processing of 
both CPY and ALP (results not shown). 
We next followed the maturation kinetics and delivery to 
the vacuole of soluble CPY and the membrane-bound alkaline 
phosphatase (ALP). Following a 15-min pulse with Tran35S-
label and a 30-min chase with unlabelled amino acids, the 
maturation of newly synthesized CPY and ALP was severely 
inhibited in spheroplasts derived from pepl2~ cells, and a 
significant portion of CPY was missorted and secreted in its 
Golgi-modified p2 precursor form (Fig. 4). The maturation of 
ALP appeared to be less affected. Most importantly, the ma-
turation and sorting defects were effectively suppressed on 
high expression of VAM3. 
To further characterize the genetic interaction of VAM3 
and PEP 12, we investigated the effect of high expression of 
the PEP 12 gene in the vam3 deletion strain YMG8. Deletion 
of the vam3 gene resulted in phenotypes previously described 
for the original vam3 mutants [8]: while the steady-state levels 
of the mature forms of PrA and CPY were comparable to 
those of wild-type cells (results not shown), the most prom-
Fig. 3. Processing of soluble vacuolar enzymes in YMG5-transform-
ants under steady-state conditions. Cell extracts of YMG5 trans-
formed with the plasmids indicated were subject to SDS-PAGE and 
Western blotting with anti-CPY (upper panel) and anti-PrA-anti-
bodies (lower panel) as described in Section 2. The migration posi-
tions (in kDa) of molecular mass markers are indicated on the left 
margin. The migration positions of the precursor (p) and mature 
(m) forms of CPY and PrA are indicated on the right margin. pPrA 
indicates the position of the largest (52 kDa) PrA precursor. 
inent phenotype was a highly fragmented vacuole (Fig. 5a,b). 
High expression of the PEP12 gene in YMG8 cells resulted in 
a partial suppression of this phenotype. Although still frag-
mented, the vacuoles of vam3 cells transformed with pRS326-
PEP12 (Fig. 5e,f) appeared larger than the vacuoles of control 
cells (Fig. 5a,b). However, the single large vacuoles of YMG8 
transformed with pRS316-VAM3 (Fig. 5c,d) were not seen. 
4. Discussion 
Pepl2p has been suggested by Becherer et al. [15] to act in 
transport of Golgi-derived vesicles carrying soluble vacuolar 
enzymes to a late endosomal ('prevacuolar') compartment and 
it was shown that the membrane-bound ALP might be trans-
ported via a Pepl2p-independent route. There is evidence that 
the transport pathways of vacuolar hydrolases and of endo-
cytosed oc-factor merge [13,38^-0] and it is well possible that 
some or all of the vacuolar proteins that pass the Golgi ap-
Fig. 4. Rescue from transport defects of newly synthesized vacuolar 
hydrolases in pepl2 null mutant cells. Spheroplasts of YMG5 cells 
transformed with either pRS326, pRS326-PEP12 or pPR326-VAM3 
were subjected to a pulse-chase with Tran35S-label. Zero or 30 min 
after initiating the chase, anti-ALP (upper panel) or anti-CPY (low-
er panel) antiserum was used for immunoprecipitation. i, internal 
fraction; e, secreted fraction. The migration positions of the precur-
sor (p) and mature (m) forms of ALP and CPY (in kDa) are indi-
cated to the right. plCPY, ER-modified form of CPY; p2CPY, 
Golgi-modified form of CPY. 
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quired for vacuole/vacuole fusion [46] lends credence to the 
assumption that Vam3p acts as a t -SNARE at the vacuole. 
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